Idexx Laboratories Director Cashes In on Stock Sale

New insider activity at Idexx Laboratories ( (IDXX) ) has taken place on May 24, 2025.

Director Anne Szostak recently sold 2,306 shares of Idexx Laboratories stock, amounting to a total transaction value of $1,182,907.

Recent Updates on IDXX stock

Idexx Laboratories recently reported a 4% increase in Q1 revenue to $998 million, driven by growth in its Companion Animal Group and Water segments. The company launched IDEXX Cancer Dx for early canine lymphoma detection, highlighting its commitment to innovation. Despite strong international growth and successful product launches, challenges such as a decline in U.S. clinical visits and macroeconomic pressures were noted. Analysts have adjusted price targets due to these mixed results, with some citing the decline in U.S. clinical visits and macroeconomic challenges as reasons for the adjustments. Idexx raised its 2025 revenue guidance, reflecting a positive foreign exchange impact and maintaining a consistent outlook for organic revenue growth.

Spark’s Take on IDXX Stock

According to Spark, TipRanks’ AI Analyst, IDXX is a Outperform.

Idexx Laboratories scores well due to its robust financial performance, particularly in profitability and cash flow generation. While technical indicators show positive momentum, valuation concerns arise from a high P/E ratio. Positive earnings sentiment is tempered by challenges in U.S. clinical visits and macroeconomic conditions. Overall, the company is well-positioned for growth in the Medical Diagnostics & Research sector.

To see Spark’s full report on IDXX stock, click here.

More about Idexx Laboratories

YTD Price Performance: 23.48%

Average Trading Volume: 862,655

Technical Sentiment Signal: Strong Buy

Current Market Cap: $40.6B